Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.

Trial Details

NCT ID
NCT04643366
Phase
PHASE2
Sponsor
Virginia Commonwealth University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Chemotherapy
  • Radiation Therapy
Locations (sample)
  • Richmond, Virginia, United States|37.55376,-77.46026
  • Richmond, Virginia, United States|37.55376,-77.46026
  • South Hill, Virginia, United States|36.72653,-78.12889
  • Tappahannock, Virginia, United States|37.92541,-76.85913

Key Eligibility Criteria

  • Pathologic diagnosis of adenocarcinoma of the rectum (diagnosis by tissue biopsy) within 90 days prior to registration. At least a portion of the t…
  • Clinically staged (AJCC 8th ed.) T3-4 N0 M0 or T any N1-2 M0 based upon the following minimum diagnostic workup:
  • Colonoscopy, unless patient presents with an obstructing lesion
  • Within 30 days before initiating MFOLFOX6 treatment:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →